Vlad is running out of financing options. In not so many words he has said that today. If no non-dilutive financing can be found, he will struggle to raise at all, let alone at 1p. What a spot to be in with so much going for the company from a science perspective.
Disgrace these 2 are.
Condemning people who were allegedly deramping, whilst all the time they were ramping. Where are they now? Nowhere to be seen.
And hedgbackwards even started that rubbish about going to the FCA - couldnt make it up.
How farcical.
Almost mid June, no news from Vlad. I believe he simply has not got the funds to complete Ph 1 - he may be able to start but not finish.
Increasingly, by his own admission, hard to raise in the current climate.
What is the company going to do? Unless im wrong, I believe the board is stuck and struggling to find a way forward.
Another raise will be 30% from current SP, meaning, if he raised soon, it will be around 1p. Of course he may have an institution interested, but that's probably wishful thinking. Or, he could sell the science as it currently stands. Or, they may have a breakthrough with CBR, but historics point to CBR being a raise catalyst.
Tricky.
Expect a couple very soon I'd say.
Yawn.....
Why some believe trading commentary on forums is of interest staggers me, never understood it.
Is Vlad finally out of options? How can he possibly progress without further funding and where is that coming from?
And where are the old faithfuls? Hedge. JHFH. The usual lot.
Is Vlad to pharma what George Roach is to lithium?
Just need Redwood to start up again, head towards 20%.
Patience pays.
Thats what im trying to allude to, 1 patient, which shows promise, could be an opening that the Vlad needs to secure substantial funding? So, perhaps knowledge and lead time of the first person sees the stock stabalise in terms of SP?
And HT - Im not deramping, I think the SP says it all, so why dont you just have a reality check and understand the SP has got nothing to do with adhoc posts I may make! Silly boy.
What do you think the the cash position is Haywain? Maybe £3m?
Do you think 1 person goes to trial, and if the results are favourable from 1, they raise or do a JV from that? Would 1 be enough? Im thinking probably not but Im not an industry expert.
HT - Because I follow the company and see how disppointing things are for the science, the research they team has done, and for what? To be under severe funding pressure. It is a shame, thats all HT. Nothing else.
Additionally, where is JHFH? He who said so many things about a clin trial company being no less than £100m CAP > I got slated for "deramping", but JFH has been ramping all along, even if unknowingly so! Where is HedgeBackwards?
They aint here are they! Theyve either lost lots, down lots, or made lots! You decide.
As an investor, where is the value now in HEMO, in terms of science versus funding? I am not in, and unlike previous times, I don't see what the short and medium term bring for HEMO. The company is marked down so much that raising again will be 1.5p or even 1.2p.
The BoD has allowed too many trading opportunities for a product that it potentially life saving. I go back to what I said previously, I think they're looking for an exit to go private.
Unless a JV with a global pharma is announced, Vlad seems to have played his deck on LSE.
That's the thing, HEMO hasnt got a healthy cash balance. The cash is "committed" to starting trials. It's already spent (forecast spent), that's why non-dilutive funding critical.